Document is current
Any future updates will be listed below
-
Authors
Natarajan, Siva Kumar
Lum, Joanna
Skeans, James Haggerty
Nenwani, Minal
Eyunni, Sanjana
Mota, Mateus
Bayliss, Jill M. https://orcid.org/0000-0002-7995-5584
Deogharkar, Akash
Hamanishi, Erin Taya
Pun, Matthew
Sweha, Stefan R.
Hoffman, Simon https://orcid.org/0009-0000-1385-6316
Young, Eleanor https://orcid.org/0000-0001-5393-530X
Zhang, Qiuyang
Mehta, Rijul
Animasahun, Olamide https://orcid.org/0000-0002-4032-3619
Narayanan, Pranav
Sunil, Sushanth
Parolia, Abhijit
Sajjakulnukit, Peter https://orcid.org/0000-0002-8556-7481
Panwalkar, Pooja
Doherty, Robert
Clausen, Madison https://orcid.org/0009-0007-1460-5464
Dang, Derek
Hawes, Debra
Yang, Fusheng https://orcid.org/0000-0002-8040-6312
Santi, Mariarita
Judkins, Alexander R.
Wilson, Yelena
Vigil, Thomas
Franson, Andrea https://orcid.org/0000-0002-5361-7683
Mortensen, Richard M.
Ozawa, Tatsuya
Griesinger, Andrea
Holland, Eric C. https://orcid.org/0000-0002-3792-7120
Foreman, Nicholas K.
Michealraj, Kulandaimanuvel Antony https://orcid.org/0000-0002-3967-0816
Agnihotri, Sameer
Taylor, Michael https://orcid.org/0000-0001-7009-3466
Gilbertson, Richard J. https://orcid.org/0000-0001-7539-9472
Koschmann, Carl
Chinnaiyan, Arul M. https://orcid.org/0000-0001-9282-3415
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Nagrath, Deepak https://orcid.org/0000-0002-8999-2282
Venneti, Sriram
- License Information
-
More Information
Article History
Received: 8 July 2023
Accepted: 4 December 2025
First Online: 4 February 2026
Competing interests
: S.K.N., J.L. and S.V. are listed as inventors on US provisional patent 63/919,979. A.M.C. is a co-founder and serves on the Scientific Advisory Board of Lynx Dx, Esanik Therapeutics, Medsyn and Flamingo Therapeutics. A.M.C. is a scientific consultant for EdenRoc, Proteovant, Aurigene Oncology, RAPPTA, Belharra and Tempus. C.A.L. has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1 pathway as a therapeutic approach (US patent 2015126580-A1, 05/07/2015; US patent 20190136238, 05/09/2019; international patent WO2013177426-A2, 04/23/2015).
